Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 213

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction: Results From DHART2

Open access
Van Tassell, Benjamin W., Trankle, Cory R., Canada, Justin M., Carbone, Salvatore, Buckley, Leo, Kadariya, Dinesh, Del Buono, Marco G., Billingsley, Hayley, Wohlford, George, Viscusi, Michele, Oddi-Erdle, Claudia, Abouzaki, Nayef A., Dixon, Dave, Biondi-Zoccai, Giuseppe, Arena, Ross, Abbate, Antonio · 2018 · Circulation: Heart Failure

Abstract

Background: Enhanced inflammation may lead to exercise intolerance in heart failure with preserved ejection fraction. The aim of the current study was to determine whether IL (interleukin)-1 blockade with anakinra improved cardiorespiratory fitness in heart failure with preserved ejection fraction. Methods and Results: Thirty-one patients with heart failure with preserved ejection fraction and CRP (C-reactive protein) >2 mg/L were randomized to anakinra (100 mg subcutaneously daily, N=21) or placebo (N=10) for 12 weeks. We measured peak oxygen consumption (V o 2 ), ventilatory efficiency (V E /V co 2 slope), and high-sensitivity CRP and NT-proBNP (N-terminal pro-B-type natriuretic peptide) at 4, 12, and 24 weeks. Twenty-eight patients completed ≥2 visits, 18 women (64%), 27 (96%) obese. There were no differences in peak V o 2 or V E /V co 2 slope between groups at baseline. Peak V o 2 was not changed after 12 weeks of anakinra (from 13.6 [11.8–18.0] to 14.2 [11.2–18.5] mL·kg −1 ·min −1 , P =0.89), or placebo (14.9 [11.7–17.2] to 15.0 [13.8–16.9] mL·kg −1 ·min −1 , P =0.40), without significant between-group differences in changes at 12 weeks (−0.4 [95% CI, −2.2 to +1.4], P =0.64). V E /V co 2 slope was also unchanged with anakinra (from 28.3 [27.2–33.0] to 30.5 [26.3–32.8], P =0.97) or placebo (from 31.6 [27.3–36.9] to 31.2 [27.8–33.4], P =0.78), without significant between-group differences in changes at 12 weeks (+1.2 [95% CI, −1.8 to +4.3], P =0.97). Within the anakinra-treated patients, high-sensitivity CRP and NT-proBNP levels were lower at 4 weeks compared with baseline ( P =0.026 and P =0.022 versus placebo [between-group analysis], respectively). Conclusions: Treatment with anakinra for 12 weeks failed to improve peak V o 2 and V E /V co 2 slope in a group of obese heart failure with preserved ejection fraction patients. The favorable trends in high-sensitivity CRP and NT-proBNP with anakinra deserve exploration in future studies. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02173548.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circheartfailure.118.005036

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 213

Metadata

Authors
Van Tassell, B. W., Trankle, C. R., Canada, J. M., Carbone, S., Buckley, L., Kadariya, D., Del Buono, M. G., Billingsley, H., Wohlford, G., Viscusi, M., Oddi-Erdle, C., Abouzaki, N. A., Dixon, D., Biondi-Zoccai, G., Arena, R., & Abbate, A.
Venue
Circulation: Heart Failure
Published
2018-08
Volume
11
Issue
8
Pages
e005036-e005036
ISSN
  • 1941-3289 (ISSN-L)
  • 1941-3297
OpenAlex
W2898718238
Cited by
213
References
6
FWCI
12.04
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction: Results From DHART2. https://app.cochat.ai/papers/10.1161/circheartfailure.118.005036
The paper
Van Tassell, B. W., Trankle, C. R., Canada, J. M., Carbone, S., Buckley, L., Kadariya, D., Del Buono, M. G., Billingsley, H., Wohlford, G., Viscusi, M., Oddi-Erdle, C., Abouzaki, N. A., Dixon, D., Biondi-Zoccai, G., Arena, R., & Abbate, A. (2018). IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction: Results From DHART2. Circulation: Heart Failure. https://doi.org/10.1161/circheartfailure.118.005036

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.